Form 4: Bluebird Bio CEO Andrew Obenshain Acquires Shares Following Performance Stock Unit Vesting

Andrew Obenshain, President and CEO of bluebird bio, acquired 763 shares of common stock following the vesting of a performance stock unit award.

Summary

• On February 10, 2025, Andrew Obenshain, the President and CEO of bluebird bio, acquired 763 shares of common stock.
• The acquisition was a result of the vesting of a performance stock unit (PSU) award granted on February 1, 2022.
• The Compensation Committee of the Board of Directors determined on February 9, 2025, that certain performance conditions for the PSU had been satisfied.
• The shares were acquired at a price of $0.00.
• Following the transaction, Obenshain directly owns 19,248 shares of bluebird bio.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The vesting of PSUs indicates that performance goals were met, which is generally a good sign. The CEO increasing their stake in the company is also a positive signal.

Positives

• The vesting of performance stock units suggests that the company has met certain performance goals set by the board.
• The CEO's increased stake in the company could be seen as a positive signal to investors.

Industry Context

This type of transaction is common for executives who receive stock-based compensation as part of their overall package. It aligns their interests with those of the shareholders.

Stakeholder Impact

• Shareholders may view the CEO's increased ownership as a positive sign, aligning management's interests with theirs.

Key Dates